Skintensive, an award-winning and science-backed skincare brand founded by two Harvard-trained dermatologists, is thrilled to announce its plans for expansion in 2024. Known for its clinically-tested and top-selling Bruise Cream and a skincare range designed to support maturing and sensitive skin, Skintensive welcomes industry veteran, Dr. John Bartolone Ph.D., and acquires ScarSmart, a scar improvement and prevention brand.
Bartolone joins Skintensive co-founders Anar Mikailov, M.D., FAAD, and Vladimir Ratushny, M.D., Ph.D., FAAD, as Chief Science Officer. With over 30 years of experience leading research and development labs in two of the world’s biggest personal care brands, Procter & Gamble and Unilever, Dr. Bartolone has launched numerous “first-of-its-kind” technologies and products in skincare and haircare. Pioneering core global science platforms, including anti-aging and skin lightening, Dr. Bartolone most recently launched Unilever’s first plant-based preservative system.
Bartolone joins Skintensive co-founders Anar Mikailov, M.D., FAAD, and Vladimir Ratushny, M.D., Ph.D., FAAD, as Chief Science Officer. With over 30 years of experience leading research and development labs in two of the world’s biggest personal care brands, Procter & Gamble and Unilever, Dr. Bartolone has launched numerous “first-of-its-kind” technologies and products in skincare and haircare. Pioneering core global science platforms, including anti-aging and skin lightening, Dr. Bartolone most recently launched Unilever’s first plant-based preservative system.
Prior to pivoting to cosmetics, Dr. Bartolone was an Assistant Professor at the University of Connecticut, where he was awarded the “Best Paper of the Year” from the Society of Toxicology for ground-breaking research on Acetaminophen Hepatotoxicity.
“I was impressed when I first met Dr. Mikailov and Dr. Ratushny in how they found an underserved, white space in the otherwise saturated skincare industry,” said Dr. Bartolone. “They’re seeing patients daily in clinics and using that direct patient feedback along with their expertise to create truly functional products. I’m honored to bring my experience and expertise to Skintensive as the brand continues expanding.”
“I was impressed when I first met Dr. Mikailov and Dr. Ratushny in how they found an underserved, white space in the otherwise saturated skincare industry,” said Dr. Bartolone. “They’re seeing patients daily in clinics and using that direct patient feedback along with their expertise to create truly functional products. I’m honored to bring my experience and expertise to Skintensive as the brand continues expanding.”
“Dr. Mikailov and I are humbled and excited for John Bartolone to join us at Skintensive,” said Dr. Ratushny. “Not only does he provide an encyclopedic insight into the skincare industry, his experience in product development, brand positioning, and creating breakthrough innovations is truly invaluable.”
In addition to the appointment of John Bartolone, Skintensive is excited to announce the acquisition of Scar Smart, the makers of Scar Smart Silicone Scar Gel and Scar Smart Silicone Scar Sheets. Scar Smart is a proven silicone-based scar revision product line that will expand Skintensive’s product offering of functional skincare solutions.
"We initially developed the Skintensive Bruise Cream to address acute and chronic bruising and solar purpura that is exceedingly common in our patients,” said Dr. Mikailov. “Those same patients also need options for the prevention and improvement of scars on their fragile skin. Now, the patients who trust our Skintensive brand will have access to an incredible product that dermatologists have recommended for many years."
The Skintensive brand is carried by numerous board-certified dermatologist offices in the United States and will be exhibited at the 2024 American Academy of Dermatology conference in San Diego from March 7th through the 11th. Skintensive’s expansion in 2024 reflects the brand’s strong sales growth and its commitment to delivering cutting-edge, high-quality, expert-driven skincare solutions. With the addition of Dr. Bartolone and the acquisition of Scar Smart, Skintensive is well-positioned to continue its growth trajectory and strengthen its position through 2024 and beyond.
About Skintensive
Founded by two Harvard-trained dermatologists, Skintensive develops science-backed and clinically-tested skincare designed to support aging skin. Best known for the Skintensive Bruise Cream, the company ensures that each formula is grounded in research and crafted to perfection through rigorous testing.
About Anar Mikailov, MD. FAAD
Dr. Mikailov is a Harvard-trained dermatologist with an expertise in high-risk skin cancer and medical dermatology. He is the author of the world-famous Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology 9th edition, the best-selling dermatology textbook. He is dual-boarded in both Internal Medicine and Dermatology.
Dr. Mikailov is a Harvard-trained dermatologist with an expertise in high-risk skin cancer and medical dermatology. He is the author of the world-famous Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology 9th edition, the best-selling dermatology textbook. He is dual-boarded in both Internal Medicine and Dermatology.
Recognized as a leader in consultative hospital dermatology, Dr. Mikailov has published extensively and presented internationally. He practices medical and consultative dermatology full-time in Rochester, NY.
About Vladimir Ratushny, M.D. Ph.D. FAAD
Dr. Ratushny is a Harvard-trained dermatologist and fellowship-trained Mohs surgeon. He is well-known for his expertise in Mohs surgery, high-risk skin cancer management, general dermatology, and hair transplantation.
During the course of his Ph.D. at Fox Chase Cancer Center, Dr. Ratushny discovered two new drug combination therapies for cancer, one of which went on to be tested in a clinical trial for lung cancer patients. Dr. Ratushny’s original research, case reports, and review articles have been published in numerous peer-reviewed journals in areas ranging from skin cancer, drug resistance mechanisms, Lyme disease, allergic contact dermatitis, and medical humanities.
Media Contact